Physician profile
James Klancnik
NPI 1932134491
$872.06
in general payments reported to CMS, 2019-2025
11 companies · $98.52 in 2025
The $98.52 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.12 · 2020: $16.28 · 2021: $50.02 · 2022: $210 · 2023: $213 · 2024: $205 · 2025: $98.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $515.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $190.20 | 2019-2022 | |
| Astellas Pharma US INC | $187.64 | 2023-2024 | Izervay |
| Genentech, INC. | $150.00 | 2022 | |
| Abbvie INC. | $121.35 | 2024-2025 | |
| Genentech USA, INC. | $113.53 | 2023-2024 | Vabysmo, Lucentis |
| Bausch & Lomb Americas INC. | $40.14 | 2024 | Miebo, Xiidra |
| Tarsus Pharmaceuticals, INC. | $26.92 | 2024 | Xdemvy |
| Alimera Sciences, INC. | $26.00 | 2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $16.28 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Klancnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.